Strategic Focus Targeting glioblastoma and other solid tumors with gamma-delta T cell therapies positions IN8bio for collaborations with oncology-focused pharma and academic groups seeking novel, peer-reviewed immunotherapy approaches.

Clinical Leadership IN8bio is the most clinically advanced gamma-delta T cell company and has published peer-reviewed data in journals like JCO and Nature Communications, which can be leveraged to engage institutional partners and CDMOs on co-development opportunities.

DeltEx Platform DeltEx enables allogeneic, autologous, and genetically modified gamma-delta T cell therapies, offering versatile collaboration angles with biotech developers and contract manufacturing organizations seeking scalable, specialized cell manufacturing capabilities.

Clinical Evidence Updated survival and progression data showing meaningful improvements in glioblastoma outcomes provide a compelling value proposition for potential licensing, co-development, or sponsored research with cancer centers and payers evaluating new standard-of-care enhancers.

Engager Pipeline Next-generation gamma-delta T cell engagers and combination therapy platforms present upsell potential to partners exploring synergistic immunotherapies, expanding conversations beyond cell therapy to multi-modal treatment strategies.